ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0842

The Incident Risk and Predictors of Systemic Autoimmune Rheumatic Disease (SARD) Development in Persistently Antiphospholipid Antibody Positive Patients Without SARDs: Prospective Results from the APS ACTION Clinical Database and Repository (“Registry”)
Abstract Number: 1520

The Influence of Trauma on Features of Type 2 SLE
Abstract Number: 2010

The Influence of Treat-to-target Urate Lowering Therapy and Anti-inflammatory Prophylaxis on Circulating Measures of Inflammation in Gout
Abstract Number: 0979

The Joint Project: A Community-Based, Barangay Health Worker-Led Screening Program for Childhood Musculoskeletal Disorders in a Barangay in San Pedro, Laguna, Philippines
Abstract Number: 1082

The Journey of a Patient with Psoriatic Arthritis: The Path from Diagnosis to Treatment
Abstract Number: 2535

The Lipidomic and Proteomic Profiles in Antiphospholipid Syndrome Patients Are Intricately Linked to Disease Pathogenesis and Modulated by Ubiquinol Supplementation
Abstract Number: 0569

The Longitudinal Association Between Disease Activity, Function and Health-Related Quality of Life in Axial Spondyloarthritis: Results from the DESIR Cohort
Abstract Number: 0838

The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS
Abstract Number: 0609

The Mediating Role of Trust in Usual Rheumatologists on the Relationship Between Multidimensional Health Literacy and Medication Adherence Among Japanese Systemic Lupus Erythematosus Patients
Abstract Number: 2498

The Methylome Profile of B-cells as a Biomarker of Nephritis in IgA Vasculitis
Abstract Number: 1953

The National Trend of Using Prescription Immunosuppressives
Abstract Number: 2413

The Natural History of SLE Has Changed Since the 1970s
Abstract Number: 1108

The Needed Daily Dose of Colchicine in Patients with Familial Mediterranean Fever May Be Higher in Women, a Study on Behalf of the JIR Cohort
Abstract Number: 1059

The Negative Impact of Physicians’ Neuroticism and Conscientiousness on Shared Decision Making in Patients with Systemic Lupus Erythematosus: The TRUMP2-SLE Project
Abstract Number: 0854

The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].